{"entity":{"id":"nct06976944","kind":"trial","name":"Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer","aka":["PRELUDE"],"tldr":"A phase 2 trial of pembrolizumab, paclitaxel / nab-paclitaxel and bevacizumab in triple-negative breast cancer, run by Yukinori Ozaki, now recruiting.","summary":"Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer is a phase 2, randomised interventional study registered as NCT06976944 by Yukinori Ozaki, with a registry enrolment figure of 24 participants, started 2025-06-24 and due to reach its primary completion in 2029-09. Interventions recorded: Pembrolizumab; Paclitaxel; Bevacizumab. Conditions listed: Recurrent Triple-Negative Breast Cancer. Triple-negative eligibility wording from the registry: \"Participants must have recurred after treatment with an anti-PD-1/PD-L1 antibody administered as monotherapy or in combination with other ICIs or chemotherapies as a perioperative drug therapy for triple negative breast cancer\". Sites: Japan. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06976944","url":"https://clinicaltrials.gov/study/NCT06976944"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-metastatic"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy"],"targets":[],"drugs":["pembrolizumab","paclitaxel","bevacizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06976944","phase":"2","setting":"Randomized Phase II Study of Pembrolizumab + Paclitaxel +/- Bevacizumab in Patients With Recurrent Triple-Negative Breast Cancer Who Received Perioperative Immunotherapy","sponsor":"Yukinori Ozaki","enrolled":24,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06976944/","neighbours":{"cancer":[{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}